Joyce A. O'Shaughnessy, MD

A broad review of strategies to manage interstitial lung disease, including steroid use, therapy cessation/rechallenging, and dose reduction.

Brief considerations for the impact an agent’s therapeutic class can have on how interstitial lung disease should be approached.

Experts consider the mainstays in ILD management and factors that may dictate one treatment strategy over another.

Joyce A. O'Shaughnessy, MD, discusses the utility of tucatinib in HER2-positive breast cancer with brain metastases.

Joyce A. O'Shaughnessy, MD, discusses the utility of targeting capivasertib in targeting Akt mutations in breast cancer.

Joyce A. O’Shaughnessy, MD, chair of Breast Cancer Research and the Celebrating Women Chair in Breast Cancer at Baylor-Sammons Cancer Center, Texas Oncology, and chair of The US Oncology Network, and 2016 Giant of Cancer Care in Community Outreach, discusses the future role of chemotherapy in the treatment landscape of triple-negative breast cancer.

Joyce A. O’Shaughnessy, MD, chair of Breast Cancer Research and the Celebrating Women Chair in Breast Cancer at Baylor-Sammons Cancer Center, discusses differentiating between CDK 4/6 inhibitors in breast cancer.

Joyce A. O'Shaughnessy, MD, Texas Oncology-Baylor Charles A. Sammons Cancer Center, discusses new developments in molecular profiling in patients with metastatic breast cancer.

Joyce A. O'Shaughnessy, MD, Texas Oncology-Baylor Charles A. Sammons Cancer Center, discusses how the results of phosphoprotein assays can impact treatment decisions for select patients with advanced breast cancer.

Joyce A. O'Shaughnessy, MD, Texas Oncology-Baylor Charles A. Sammons Cancer Center, discusses insights from adding phosphoprotein testing to genomic testing for patients with breast cancer.

Joyce A. O'Shaughnessy, MD, Texas Oncology-Baylor Charles A. Sammons Cancer Center, discusses what recent research has shown regarding phosphoprotein assays in treatment decision-making for patients with breast cancer.

Joyce A. O'Shaughnessy, MD, discusses the evolving area of breast cancer subtype-specific cytotoxic agents.

Joyce A. O'Shaughnessy, MD, from the Baylor Charles A. Sammons Cancer Center, reviews findings from Study 301, which compared eribulin mesylate to capecitabine for patients with locally advanced or metastatic breast cancer.

Joyce A. O'Shaughnessy, MD, the Co-Director of Breast Cancer Research at the Baylor Charles A. Sammons Cancer Center, describes potentially practice changing findings from the BOLERO-3 trial.

Dr. Joyce A. O'Shaughnessy from the Baylor Sammons Cancer Center Describes the School of Breast Oncology

Dr. Joyce A. O'Shaughnessy from Baylor Sammons Cancer Center on the Future of Triple Negative Breast Cancer Treatment

Dr. Joyce A. O'Shaughnessy from Baylor Sammons Cancer Center on the Future of Breast Cancer Treatment

Dr. Joyce A. O'Shaughnessy from Baylor Sammons Cancer Center on the Future of Breast Cancer Biomarkers

Dr. Joyce O'Shaughnessy from Baylor Sammons Cancer Center on Negative TNBC Iniparib Trial Results

Dr. Joyce A. O'Shaughnessy from Baylor Sammons Cancer Center on Avastin as Her Standard of Care

Dr. Joyce A. O'Shaughnessy from Baylor Sammons Cancer Center on Continued Access to Avastin